301 related articles for article (PubMed ID: 32090517)
1. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.
Wadden TA; Tronieri JS; Sugimoto D; Lund MT; Auerbach P; Jensen C; Rubino D
Obesity (Silver Spring); 2020 Mar; 28(3):529-536. PubMed ID: 32090517
[TBL] [Abstract][Full Text] [Related]
2. Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.
Tronieri JS; Fabricatore AN; Wadden TA; Auerbach P; Endahl L; Sugimoto D; Rubino D
Obes Facts; 2020; 13(6):572-583. PubMed ID: 33197917
[TBL] [Abstract][Full Text] [Related]
3. Effects of Liraglutide and Behavioral Weight Loss on Food Cravings, Eating Behaviors, and Eating Disorder Psychopathology.
Chao AM; Wadden TA; Walsh OA; Gruber KA; Alamuddin N; Berkowitz RI; Tronieri JS
Obesity (Silver Spring); 2019 Dec; 27(12):2005-2010. PubMed ID: 31746553
[TBL] [Abstract][Full Text] [Related]
4. Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial.
Wadden TA; Walsh OA; Berkowitz RI; Chao AM; Alamuddin N; Gruber K; Leonard S; Mugler K; Bakizada Z; Tronieri JS
Obesity (Silver Spring); 2019 Jan; 27(1):75-86. PubMed ID: 30421856
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial.
Garvey WT; Birkenfeld AL; Dicker D; Mingrone G; Pedersen SD; Satylganova A; Skovgaard D; Sugimoto D; Jensen C; Mosenzon O
Diabetes Care; 2020 May; 43(5):1085-1093. PubMed ID: 32139381
[TBL] [Abstract][Full Text] [Related]
6. Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Tronieri JS; Wadden TA; Walsh OA; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Chao AM
Metabolism; 2019 Jul; 96():83-91. PubMed ID: 30902750
[TBL] [Abstract][Full Text] [Related]
7. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.
Blackman A; Foster GD; Zammit G; Rosenberg R; Aronne L; Wadden T; Claudius B; Jensen CB; Mignot E
Int J Obes (Lond); 2016 Aug; 40(8):1310-9. PubMed ID: 27005405
[TBL] [Abstract][Full Text] [Related]
8. Changes in health-related quality of life with intensive behavioural therapy combined with liraglutide 3.0 mg per day.
Chao AM; Wadden TA; Walsh OA; Gruber KA; Alamuddin N; Berkowitz RI; Tronieri JS
Clin Obes; 2019 Dec; 9(6):e12340. PubMed ID: 31691531
[TBL] [Abstract][Full Text] [Related]
9. Measures of adherence as predictors of early and total weight loss with intensive behavioral therapy for obesity combined with liraglutide 3.0 mg.
Tronieri JS; Wadden TA; Walsh O; Berkowitz RI; Alamuddin N; Chao AM
Behav Res Ther; 2020 Aug; 131():103639. PubMed ID: 32450367
[TBL] [Abstract][Full Text] [Related]
10. Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial.
Tronieri JS; Wadden TA; Walsh O; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Bakizada ZM; Chao AM
Int J Obes (Lond); 2020 Feb; 44(2):353-361. PubMed ID: 30926955
[TBL] [Abstract][Full Text] [Related]
11. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
Wadden TA; Hollander P; Klein S; Niswender K; Woo V; Hale PM; Aronne L;
Int J Obes (Lond); 2013 Nov; 37(11):1443-51. PubMed ID: 23812094
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
[TBL] [Abstract][Full Text] [Related]
13. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
[TBL] [Abstract][Full Text] [Related]
14. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
[TBL] [Abstract][Full Text] [Related]
15. Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies.
Farr OM; Upadhyay J; Rutagengwa C; DiPrisco B; Ranta Z; Adra A; Bapatla N; Douglas VP; Douglas KAA; Nolen-Doerr E; Mathew H; Mantzoros CS
Diabetes Obes Metab; 2019 Nov; 21(11):2459-2464. PubMed ID: 31282006
[TBL] [Abstract][Full Text] [Related]
16. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
Lundgren JR; Janus C; Jensen SBK; Juhl CR; Olsen LM; Christensen RM; Svane MS; Bandholm T; Bojsen-Møller KN; Blond MB; Jensen JB; Stallknecht BM; Holst JJ; Madsbad S; Torekov SS
N Engl J Med; 2021 May; 384(18):1719-1730. PubMed ID: 33951361
[TBL] [Abstract][Full Text] [Related]
17. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Astrup A; Rössner S; Van Gaal L; Rissanen A; Niskanen L; Al Hakim M; Madsen J; Rasmussen MF; Lean ME;
Lancet; 2009 Nov; 374(9701):1606-16. PubMed ID: 19853906
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
Astrup A; Carraro R; Finer N; Harper A; Kunesova M; Lean ME; Niskanen L; Rasmussen MF; Rissanen A; Rössner S; Savolainen MJ; Van Gaal L;
Int J Obes (Lond); 2012 Jun; 36(6):843-54. PubMed ID: 21844879
[TBL] [Abstract][Full Text] [Related]
19. liraglutide (SAXENDA⁰) and obesit. Still no satisfactory weight loss drugs.
Prescrire Int; 2016 Jan; 25(167):5-8. PubMed ID: 26942248
[TBL] [Abstract][Full Text] [Related]
20. The Current Role of Liraglutide in the Pharmacotherapy of Obesity.
Christou GA; Katsiki N; Kiortsis DN
Curr Vasc Pharmacol; 2016; 14(2):201-7. PubMed ID: 26074046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
